Third Arc Bio
Lower Gwynedd, US · Founded 2021 · Delaware corporation · 4 known investors
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.
Founders & leadership
JE
Joseph ErhardtExecutive Officer
PL
Peter LebowitzExecutive Officer, Director
AG
Arjun GoyalDirector
OS
Otello StampacchiaDirector
FD
Francesco DraettaDirector
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$72.5MraisedAug 2024 · 32 investors · BiotechnologyRule 506(b)
▶$72.5MraisedAug 2024 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph ErhardtExecutive Officer
- Arjun GoyalDirector
- Otello StampacchiaDirector
- Peter LebowitzExecutive Officer, Director
- Francesco DraettaDirector
- Offering amount
- $165M
- Amount sold
- $72.5M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfoliofinance.yahoo.com · 2026
- Montgomery County's Third Arc Bio raises another $52M led by top Silicon Valley VC firm - Philadelphia Business Journalbizjournals.com · 2026
- Third Arc Bio raises USD 52m in Series A for multi-function antibodies - AllSciallsci.com · 2026
- Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseasesprnewswire.com · 2024